Gadolinium-based MRI Drugs Pose Serious Health Risks
BusinessWeek recently reported that some drugs used for MRI imaging may be riskier for patients with pre-existing kidney issues than previously believed. These drugs are all gadolinium-based, and include Omniscan, Magnevist, and Optimark. Some major hospitals had already ceased use of Omniscan when reports came out in 2006 that its use may lead to an increased risk of developing a condition called nephrogenic systemic fibrosis.
Nephrogenic systemic fibrosis (NSF) is a rare, but potentially fatal disease. In May 2006, Danish medical regulators issued a warning that patients in Denmark and Austria with pre-existing kidney issues had suffered NSF after undergoing an MRI. The warning stated that the dye used to make MRI images clearer contributed to the development of NSF in these patients. Researchers in the U.S. and Europe subsequently found that gadolinium-based drugs have a higher risk of NSF than other drugs used for MRIs.
The newest development over this controversy is that the FDA is considering further regulation of Omniscan, Magnevist and Optimark. An advisory panel was scheduled to assess on December 8 whether or not new restrictions are necessary for these gadolinium-based drugs. To date, over 400 lawsuits have been filed over the drugs and their increased risk for development of NSF in patients with kidney problems.
Contact an Experienced Attorney
If you or a loved one has developed nephrogenic systemic fibrosis, and you believe that a gadolinium-based MRI drug may have been a contributing factor, contact the experienced drug litigation attorneys at the Pintas Law Firm today. We will provide you with a free no-obligation consultation and explain your legal rights.